Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

vTv Therapeutics (VTVT) EBITDA Margin (2016 - 2024)

vTv Therapeutics (VTVT) has disclosed EBITDA Margin for 10 consecutive years, with 28776.47% as the latest value for Q4 2024.

  • Quarterly EBITDA Margin changed N/A to 28776.47% in Q4 2024 from the year-ago period, while the trailing twelve-month figure was 175382.35% through Sep 2025, down 17298285.0% year-over-year, with the annual reading at 2377.58% for FY2024, N/A changed from the prior year.
  • EBITDA Margin hit 28776.47% in Q4 2024 for vTv Therapeutics, down from 562.7% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 28.6% in Q4 2020 to a low of 123433.33% in Q4 2021.
  • Historically, EBITDA Margin has averaged 37016.52% across 4 years, with a median of 34616.81% in 2024.
  • Biggest five-year swings in EBITDA Margin: skyrocketed 9128574bps in 2020 and later plummeted -12346193bps in 2021.
  • Year by year, EBITDA Margin stood at 28.6% in 2020, then tumbled by -431712bps to 123433.33% in 2021, then soared by 43bps to 70477.78% in 2022, then surged by 59bps to 28776.47% in 2024.
  • Business Quant data shows EBITDA Margin for VTVT at 28776.47% in Q4 2024, 562.7% in Q1 2024, and 70477.78% in Q4 2022.